P29. Oral topotecan in small cell lung cancer: treatment related side effects

Por Popovic, Filip, Samarzija, Miroslav, Kukulj, Suzana, Redzepi, Gzim, Roglic, Mihovil, Mursic, Davorka, Cucevic, Branka, Plestina, Sanja, Jakopovic, Marko
Publicado no Transl Lung Cancer Res (2014)

Decision analytic modeling for the economic analysis of proton radiotherapy for non-small cell lung cancer

Por Smith, Wade P., Richard, Patrick J., Zeng, Jing, Apisarnthanarax, Smith, Rengan, Ramesh, Phillips, Mark H.
Publicado no Transl Lung Cancer Res (2018)

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Por De Leyn, Paul, Dooms, Christophe, Kuzdzal, Jaroslaw, Lardinois, Didier, Passlick, Bernward, Rami-Porta, Ramon, Turna, Akif, Van Schil, Paul, Venuta, Frederico, Waller, David, Weder, Walter, Zielinski, Marcin
Publicado no Transl Lung Cancer Res (2014)

Treatment of advanced squamous cell carcinoma of the lung: a review

Por Derman, Benjamin A., Mileham, Kathryn F., Bonomi, Philip D., Batus, Marta, Fidler, Mary J.
Publicado no Transl Lung Cancer Res (2015)

Transcriptomic changes induced by mycophenolic acid in gastric cancer cells

Por Dun, Boying, Sharma, Ashok, Xu, Heng, Liu, Haitao, Bai, Shan, Zeng, Lingwen, She, Jin-Xiong
Publicado em 2013

Comparison between endobronchial ultrasound-guided transbronchial biopsy and CT-guided transthoracic lung biopsy for the diagnosis of peripheral lung cancer: a systematic review and meta-analysis

Por Zhan, Ping, Zhu, Qing-Qing, Miu, Ying-Ying, Liu, Ya-Fang, Wang, Xiao-Xia, Zhou, Ze-Jun, Jin, Jia-Jia, Li, Qian, Sasada, Shinji, Izumo, Takehiro, Tu, Chih-Yen, Cheng, Wen-Chien, Evison, Matthew, Lv, Tang-Feng, Song, Yong
Publicado no Transl Lung Cancer Res (2017)

Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study

Por Khandekar, Melin J., Jain, Rakesh
Publicado no Transl Cancer Res (2018)

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors

Por Sehgal, Kartik, Patell, Rushad, Rangachari, Deepa, Costa, Daniel B.
Publicado no Transl Cancer Res (2018)

From the bench to the bedside—promoting the roles of nurses and allied health professionals in the management of lung cancer and mesothelioma

Por White, John
Publicado no Transl Lung Cancer Res (2016)

Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer

Por Malhotra, Jyoti, Jabbour, Salma K.
Publicado no Transl Lung Cancer Res (2018)

Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?

Por Chatwal, Monica S., Tanvetyanon, Tawee
Publicado no Transl Lung Cancer Res (2018)

EGFR-TKIs in EGFR-mutated lung cancer: Setting the new standard for 1(st) line therapy

Por Wolf, Jürgen
Publicado no Transl Lung Cancer Res (2012)

Treating epidermal growth factor receptor-mutated non-small cell lung cancer—is dacomitinib the winner?

Por Dempke, Wolfram C. M., Fenchel, Klaus
Publicado no Transl Lung Cancer Res (2017)

ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients

Por Bagai, Rakesh, Pennell, Nathan A.
Publicado no Transl Lung Cancer Res (2013)

Which patients with extensive stage small-cell lung cancer should and should not receive thoracic radiotherapy?

Por Slotman, Berend J., van Tinteren, Harm
Publicado no Transl Lung Cancer Res (2015)

New insights into the functional consequences of ephrin A3 mutations in non-small cell lung cancer

Por Whitsett, Timothy G., Loftus, Joseph C., Winkles, Jeffrey A., Tran, Nhan L.
Publicado no Transl Lung Cancer Res (2013)

Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions

Por Warren, Graham W., Ward, Kenneth D.
Publicado no Transl Lung Cancer Res (2015)

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Por Jabbour, Salma K., Berman, Abigail T., Simone, Charles B.
Publicado no Transl Lung Cancer Res (2017)

Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning

Por Klempner, Samuel J., Raufi, Alexander, Ou, Sai-Hong Ignatius
Publicado no Transl Lung Cancer Res (2015)

Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer

Por Lee, Howard J., Zeng, Jing, Rengan, Ramesh
Publicado no Transl Lung Cancer Res (2018)